The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
BIOSOLVE-IV Magmaris Swiss Satellite Registry is a prospective, single-arm, multicenter, nationwide open label registry. It is planned to enroll 200 subjects in up to 12 participating sites in Switzerland. After percutaneous coronary intervention (PCI) with the Magmaris scaffold and signature of the informed consent form, all subjects will be followed through hospital discharge and will undergo follow up evaluations at 6, 12 and 24 months post procedure. The follow up evaluations, part of the standard care can be either performed on site (12 months) or by phone (6 and 24 months) and according to routine clinical practice.
Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
BIOSOLVE-IV Magmaris Swiss Satellite Registry will include male and female subjects requiring a treatment of de novo coronary artery lesions with Magmaris.
Subject is ≥18 years of age
Subject must be willing to sign a Patient Informed Consent
Symptomatic coronary artery disease
Subject with a maximum of two single de novo lesions in two different major epicardial vessels
Target lesion length ≤ 21 mm by QCA or by visual estimation
Target lesion stenosis >50% and <100% by visual estimation, and TIMI flow ≥1.
Subject is eligible for Dual Anti Platelet Therapy (DAPT)
Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the scaffold size used
Pregnant and/or breastfeeding females or females who intend to become pregnant during the time of the registry
Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, heparin or any other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium, Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated
Subjects on dialysis
Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment
Documented left ventricular ejection fraction (LVEF) ≤30% as documented within maximum 6 months prior to the procedure
Heavily calcified or extremely tortuous lesions
Bifurcation lesion requiring side branch intervention, if side branches >2 mm in diameter are involved
Restenotic target lesion
Thrombus in target vessel
Target lesion is located in or supplied by a diseased (defined as vessel irregularity per angiogram and >20% stenosed lesion by visual estimation) arterial or venous bypass graft
Left main coronary artery disease
Ostial target lesion (within 5.0 mm of vessel origin)
Target vessel (including side branches) has second lesion which requires treatment according to the investigator`s discretion
Unsuccessful pre-dilatation, defined as residual stenosis rate >20% by visual estimation and/or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections)
Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained
Currently participating in another study and primary endpoint is not reached yet
Planned interventional treatment of any non-target vessel within 30 days post procedure
Planned intervention of the target vessel within 6-month after the index procedure